In‐Situ Oxygen‐Evolving Photoactive Nanococktail: The Future of Hypoxic Tumour Photodynamic Therapy

Banerjee, Samya

doi:10.1002/cbic.201900387

Cited by 3 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 times, moving from normoxic (20 % O 2 , IC 50 =4.9 μM) to hypoxia (5 % O 2 , IC 50 =14.5 μM) condition indicating the necessity of O 2 in the mechanism of cytotoxicity. This observation supported our proposed cytotoxic mechanism and indicated that although Ir3 will be an excellent photo‐chemotherapeutics for normoxic tumors but will have limited activity against hypoxic tumors, a drawback which may be overcome by design of suitable in‐Situ oxygen supplying materials [25] . Ir3 was also photocytotoxic when irradiated with 525 nm green light (11.7 J cm −2 , 30 min) gave IC 50 (light) ca.…”

Section: Resultssupporting

confidence: 80%

“…Moreover,t he cell viability vs. Ir3 concentration curve at various light doses for HepG2 cells showed that the photo-cytotoxic effect of Ir3 can be enhanced by tuning the illumination intensity (Figure 4A), indicating the excellent photo-stability of Ir3 within cancer cells during light irradi- T his observation supported our proposed cytotoxic mechanism and indicated that although Ir3 will be an excellent photo-chemotherapeutics for normoxic tumors but will have limited activity against hypoxic tumors,adrawback which may be overcome by design of suitable in-Situ oxygen supplying materials. [25] Ir3 was also photocytotoxic when irradiated with 525 nm green light (11.7 Jcm À2 ,3 0min) gave IC 50 (light) ca. 8.1 mMi nH ep-G2 cells indicating longer wavelength activation is also effective to achieve significant photocytotoxicity.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

et al. 2021

Self Cite

View full text Add to dashboard Cite

Photocatalytic anticancer profile of a IrIII photocatalyst (Ir3) with strong light absorption, high turnover frequency, and excellent biocompatibility is reported. Ir3 showed selective photo‐cytotoxicity against cisplatin‐ and sorafenib‐resistant cell lines while remaining dormant to normal cell lines in the dark. Ir3 exhibited excellent photo‐catalytic oxidation of cellular co‐enzyme, the reduced nicotinamide adenine dinucleotide phosphate (NADPH), and amino acids via a single electron transfer mechanism. The photo‐induced intracellular redox imbalance and change in mitochondrial membrane potential resulted in necrosis and apoptosis of cancer cells. Importantly, Ir3 exhibited high biocompatibility and photo‐catalytic anticancer efficiency as evident from in vivo zebrafish and mouse cancer models. To the best of our knowledge, Ir3 is the first IrIII based photocatalyst with such a high biocompatibility and photocatalytic anticancer therapeutic effect.

show abstract

Section: Resultssupporting

confidence: 80%

Section: Resultsmentioning

confidence: 99%

In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…3times,moving from normoxic (20 %O 2 ,IC 50 = 4.9 mM) to hypoxia (5 %O 2 ,I C 50 = 14.5 mM) condition indicating the necessity of O 2 in the mechanism of cytotoxicity.T his observation supported our proposed cytotoxic mechanism and indicated that although Ir3 will be an excellent photo-chemotherapeutics for normoxic tumors but will have limited activity against hypoxic tumors,adrawback which may be overcome by design of suitable in-Situ oxygen supplying materials. [25] Ir3 was also photocytotoxic when irradiated with 525 nm green light (11.7 Jcm À2 ,3 0min) gave IC 50 (light) ca. 8.1 mMi nH ep-G2 cells indicating longer wavelength activation is also effective to achieve significant photocytotoxicity.…”

Section: Resultsmentioning

confidence: 99%

In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several strategies are in pre-clinical investigation to overwhelm these limitations, including strategies to modify the tumor microenvironment by replenishing oxygen concentration, as well as the use of oxygen carriers or self-oxygen generating systems, e.g., red blood cells, perfluorocarbon NPs, etc. (Dang et al, 2017; Luo et al, 2018; Banerjee, 2019).…”

Section: Discussionmentioning

confidence: 99%

Light-Induced Therapies for Prostate Cancer Treatment

et al. 2019

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the most widespread tumors affecting the urinary system and the fifth-leading cause from cancer death in men worldwide. Despite PC mortality rates have been decreasing during the last years, most likely due to an intensification of early diagnosis, still more than 300,000 men die each year because of this disease. In this view, researchers in all countries are engaged in finding new ways to tackle PC, including the design and synthesis of novel molecular and macromolecular entities able to challenge different PC biological targets, while limiting the extent of unwanted side effects that significantly limit men's life quality. Among this field of research, photo-induced therapies, such as photodynamic and photothermal therapies (PDT and PTT), might represent an important advancement in PC treatment due to their extremely localized and controlled cytotoxic effect, as well as their low incidence of side effects and tumor resistance occurrence. Based on these considerations, this review aims to gather and discuss the last 5-years literature reports dealing with the synthesis and biological activity of molecular conjugates and nano-platforms for photo-induced therapies as co-adjuvant or combined therapeutic modalities for the treatment of localized PC.

show abstract

In‐Situ Oxygen‐Evolving Photoactive Nanococktail: The Future of Hypoxic Tumour Photodynamic Therapy

Abstract: Hypoxia‐related resistance is one of the main challenges for photodynamic therapy to overcome. This highlight discusses a few current works on possible ways to overcome this problem by in situ oxygen generation in the hypoxic core of tumours.

Cited by 3 publications

References 18 publications

In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts

Light-Induced Therapies for Prostate Cancer Treatment

Contact Info

Product

Resources

About